Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sana Biotechnology Inc SANA

Healthcare Biotechnology
Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders. It develops a pipeline of clinical product... see more

Recent & Breaking News (NDAQ:SANA)

Did Sana Biotechnology, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SANA

Accesswire November 7, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA

Accesswire November 7, 2024

Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025

GlobeNewswire November 4, 2024

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

PR Newswire October 23, 2024

Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors

PR Newswire October 3, 2024

Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference

GlobeNewswire September 30, 2024

Sana Biotechnology to Present at September 2024 Investor Conferences

GlobeNewswire August 29, 2024

Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer

GlobeNewswire August 26, 2024

Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business Updates

GlobeNewswire August 8, 2024

Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner

PR Newswire August 6, 2024

Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington's Disease and Other Glial-based Neurodegenerative Conditions

GlobeNewswire May 21, 2024

Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates

GlobeNewswire May 8, 2024

Sana Biotechnology to Present at May and June 2024 Investor Conferences

GlobeNewswire May 6, 2024

Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

GlobeNewswire February 29, 2024

Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference

GlobeNewswire February 28, 2024

Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP

GlobeNewswire February 13, 2024

Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire February 12, 2024

Sana Biotechnology Announces Pricing of Upsized Public Offering

GlobeNewswire February 8, 2024

Sana Biotechnology Announces Proposed Public Offering of Common Stock

GlobeNewswire February 7, 2024

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies

GlobeNewswire January 5, 2024